Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUNDER RAO

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1164497293
CMS profile
143231
Location
BUTLER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$15,211.55

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUNDER RAO

NPI 1164497293 · CMS profile ID 143231

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

BUTLER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164497293?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUNDER RAO, NPI 1164497293, CMS profile ID 143231. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164497293?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SUNDER RAO, NPI 1164497293, CMS profile ID 143231. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164497293?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SUNDER RAO, NPI 1164497293, CMS profile ID 143231, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 191 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1164497293?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $15,211.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kiniksa Pharmaceuticals, Ltd. $134.8206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058926823 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $4.8206/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984037373 CMS
Novartis Pharmaceuticals Corporation $11.1906/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992731663 CMS
SCPHARMACEUTICALS INC. $10.7806/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995484981 CMS
HeartFlow, Inc. $165.8506/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049010299 CMS
Amgen Inc. $13.7706/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020155057 CMS
Amgen Inc. $91.3706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020155053 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.8906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802793 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4106/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802795 CMS
Janssen Pharmaceuticals, Inc $4.9606/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912411 CMS
E.R. Squibb & Sons, L.L.C. $13.1706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252271 CMS
Novo Nordisk Inc $14.0405/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000232607 CMS
AstraZeneca Pharmaceuticals LP $18.2705/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015045379 CMS
AstraZeneca Pharmaceuticals LP $17.3405/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011768971 CMS
SANOFI-AVENTIS U.S. LLC $14.6305/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049772745 CMS
Merck Sharp & Dohme LLC $15.2305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048539925 CMS
E.R. Squibb & Sons, L.L.C. $14.6005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252277 CMS
Janssen Pharmaceuticals, Inc $124.9905/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912419 CMS
Novartis Pharmaceuticals Corporation $4.7605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992731659 CMS
PFIZER INC. $4.3105/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049391021 CMS
Amgen Inc. $6.7205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020155049 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.3605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802799 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.7405/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000407305 CMS
Amgen Inc. $8.0605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020155045 CMS
Novo Nordisk Inc $24.5505/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000232637 CMS
Merck Sharp & Dohme LLC $13.9204/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048819161 CMS
Janssen Pharmaceuticals, Inc $4.3804/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912381 CMS
Novo Nordisk Inc $103.7304/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000232655 CMS
PFIZER INC. $23.3204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050283417 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,425.0004/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802829 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.5204/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997085313 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $29.6704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984037397 CMS
Janssen Pharmaceuticals, Inc $8.2504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912389 CMS
SANOFI-AVENTIS U.S. LLC $32.3204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049772705 CMS
AstraZeneca Pharmaceuticals LP $13.4304/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011825275 CMS
Janssen Pharmaceuticals, Inc $19.7004/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912395 CMS
Janssen Pharmaceuticals, Inc $0.9404/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912403 CMS
Bayer Healthcare Pharmaceuticals Inc. $0.4004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000395511 CMS
Bayer Healthcare Pharmaceuticals Inc. $10.1004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000396901 CMS
E.R. Squibb & Sons, L.L.C. $99.5104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252219 CMS
Novartis Pharmaceuticals Corporation $18.7804/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992731643 CMS
SANOFI-AVENTIS U.S. LLC $21.0204/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049772691 CMS
SCPHARMACEUTICALS INC. $18.5704/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995479429 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.9304/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802801 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $123.3803/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802825 CMS
E.R. Squibb & Sons, L.L.C. $12.2603/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252213 CMS
Merck Sharp & Dohme LLC $14.1303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048819159 CMS
E.R. Squibb & Sons, L.L.C. $22.4003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252229 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $880.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996802817 CMS
E.R. Squibb & Sons, L.L.C. $16.6503/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016252209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,743.66 265
PY2020 $17,402.62 124
PY2021 $20,876.01 183
PY2022 $15,212.33 141
PY2023 $15,211.55 191
PY2024 $14,765.73 144
PY2025 $8,697.07 120

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $48,744.92 16
PY2024 Principal investigator $45,181.40 4
PY2023 Principal investigator $58,148.17 3
PY2022 Principal investigator $22,429.89 1
PY2021 Principal investigator $17,658.75 63
PY2020 Principal investigator $10,575.48 29
PY2019 Principal investigator $14,338.68 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,599.05 08/19/2025 Non-covered Recipient Entity
BUTLER MEMORIAL HOSPITAL
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190304507
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728411
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728407
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728409
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,543.72 03/31/2025 Non-covered Recipient Entity
BUTLER MEMORIAL HOSPITAL
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190304377
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728401
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728403
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728397
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728399
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728405
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,878.60 01/30/2025 Non-covered Recipient Entity
BUTLER HC PROVIDERS
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311927
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 01/17/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728387
Principal investigator 1 Boehringer Ingelheim International GmbH $780.00 01/17/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728389
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 01/17/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728391
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728393
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Independence Health System Cardiology-Crossroads Campus
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220728395